- Home
- CLLS vs LYEL Comparison
CLLS vs LYEL Comparison
Compare CLLS & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- LYEL
- Stock Information
- Founded
- CLLS 1999
- LYEL 2018
- Country
- CLLS France
- LYEL United States
- Employees
- CLLS N/A
- LYEL N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- LYEL Biotechnology: Pharmaceutical Preparations
- Sector
- CLLS Health Care
- LYEL Health Care
- Exchange
- CLLS Nasdaq
- LYEL Nasdaq
- Market Cap
- CLLS 299.0M
- LYEL 253.2M
- IPO Year
- CLLS 2007
- LYEL 2021
- Fundamental
- Price
- CLLS $3.49
- LYEL $17.75
- Analyst Decision
- CLLS Buy
- LYEL Hold
- Analyst Count
- CLLS 1
- LYEL 3
- Target Price
- CLLS $8.00
- LYEL $16.67
- AVG Volume (30 Days)
- CLLS 212.5K
- LYEL 37.8K
- Earning Date
- CLLS 11-03-2025
- LYEL 11-12-2025
- Dividend Yield
- CLLS N/A
- LYEL N/A
- EPS Growth
- CLLS N/A
- LYEL N/A
- EPS
- CLLS N/A
- LYEL N/A
- Revenue
- CLLS $63,438,000.00
- LYEL $60,000.00
- Revenue This Year
- CLLS N/A
- LYEL N/A
- Revenue Next Year
- CLLS $66.76
- LYEL N/A
- P/E Ratio
- CLLS N/A
- LYEL N/A
- Revenue Growth
- CLLS 223.09
- LYEL 11.11
- 52 Week Low
- CLLS $1.10
- LYEL $7.65
- 52 Week High
- CLLS $5.48
- LYEL $30.00
- Technical
- Relative Strength Index (RSI)
- CLLS 47.81
- LYEL 62.67
- Support Level
- CLLS $3.39
- LYEL $16.00
- Resistance Level
- CLLS $5.48
- LYEL $18.09
- Average True Range (ATR)
- CLLS 0.38
- LYEL 1.16
- MACD
- CLLS -0.10
- LYEL -0.09
- Stochastic Oscillator
- CLLS 6.38
- LYEL 61.70
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.